Sequoia China-backed biopharma Structure Therapeutics files for $100m US IPO

Sequoia China-backed biopharma Structure Therapeutics files for $100m US IPO

REUTERS/Eric Thayer

Structure Therapeutics, a clinical-stage biopharmaceutical company backed by venture capital investors, including Sequoia Capital China, has filed to raise $100 million in an initial public offering (IPO) in the US.

The drug maker, headquartered in California with R&D operations in China, is looking to list its American Depositary Shares (ADS) on Nasdaq under the symbol GPCR, according to its heavily-redacted filing.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter